

**NATIONAL INSTITUTES OF HEALTH
RECOMBINANT DNA ADVISORY COMMITTEE (RAC)**

110th Meeting

**NIH Campus
Building 31, Sixth Floor, C Wing, Room 10**

**December 3-5, 2007
Agenda**

Monday, December 3, 2007

8:00 AM **Call to Order and Opening Remarks**

Howard Federoff, M.D., Ph.D., Chair, NIH RAC

Tab 2474 For Your Information
 Notice of Meeting
 Conflict of Interest Guidance

8:05 AM **Minutes of the September 17-18, 2007, RAC Meeting**

RAC Reviewers: Louis Kirchhoff, M.D., M.P.H.
 Jane Flint, Ph.D.

Tab 2475 Minutes of the September 17-18, 2007, RAC Meeting

8:15 AM **Gene Transfer Safety Assessment Board Report**

Tab 2476 Responses to M-I-C-1
 Protocol List
 Protocols Not Selected for In-Depth Review and
 Public RAC Discussion

RAC Reviewers: Steven Albelda, M.D.
 Howard Federoff, M.D., Ph.D.
 Scott Strome, M.D.

8:30 AM **Followup on Serious Adverse Event in a Human Gene Transfer Trial
(OBA Protocol #0504-705) Using an Adeno-Associated Viral Vector:
Analysis of Its Scientific and Safety Implications**

RAC Reviewers: Steven Albelda, M.D.
 Jeffrey Bartlett, Ph.D.
 Stephen Dewhurst, Ph.D.
 Hildegund Ertl, M.D.
 Howard Federoff, M.D., Ph.D.
 Scott Strome, M.D.

Monday, December 3, 2007 (continued)

9:20 AM **Public Comment**

9:30 AM **Discussion of Human Gene Transfer Protocol #0710-877: A Phase II Safety and Efficacy Study Evaluating Glutamic Acid Decarboxylase Gene Transfer to the Subthalamic Nuclei in Subjects with Advanced Parkinson's Disease**

PI: Peter LeWitt, M.D., Henry Ford Health System, Southfield, MI

RAC Reviewers: Howard Federoff, M.D., Ph.D.
Jeffrey Kahn, Ph.D., M.P.H.

Ad hoc Reviewer: Nicholas Muzyczka, Ph.D., University of Florida,
Gainesville, FL
(via teleconference)

Tab 2477 Protocol

Tab 2478 OBA Summary
OBA Letter to PI on In-Depth RAC Review and
Public Discussion
Reviews from Drs. Federoff, Kahn, and Muzyczka
PI's Response

11:00 AM **Public Comment**

11:15 AM **BREAK**

11:30 AM **Discussion of Human Gene Transfer Protocol #0710-881: A Phase Ib, Open-Label Trial to Define the Safety, Tolerance, Transgene Function, and Immunological Effects of Intratumoral Injection(s) of Adenoviral Transduced Autologous Dendritic Cells Engineered to Express hIL-12 Under Control of the RheoSwitch® Therapeutic System in Subjects with Stages III and IV Melanoma**

PI: John M. Kirkwood, M.D., University of Pittsburgh, Pittsburgh, PA

RAC Reviewers: Stephen Dewhurst, Ph.D.
David Weber, M.D., M.P.H.
David Williams, M.D.

Tab 2479 Protocol

Monday, December 3, 2007 (continued)

Tab 2480 OBA Summary
 OBA Letter to PI on In-Depth RAC Review and
 Public Discussion
 Reviews from Drs. Dewhurst, Weber, and Williams
 PI's Response

1:00 PM **Public Comment**

1:15 PM **ADJOURNMENT**

Tuesday, December 4, 2007

8:00 AM **Call to Order and Opening Remarks**

Richard Vile, Ph.D., Acting Chair, NIH RAC

8:05 AM **Discussion of Human Gene Transfer Protocol #0710-878: *A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically Modified Neural Stem Cells Expressing E. Coli Cytosine Deaminase for Treatment of Recurrent High-Grade Gliomas***

PIs: Jana Portnow, M.D., City of Hope National Medical Center,
 Duarte, CA

 Karen Aboody, M.D., City of Hope National Medical Center,
 Duarte, CA

RAC Reviewers: Ellen Grant, Ph.D., LCSW-R
 Nikunj Somia, Ph.D.
 Richard Vile, Ph.D.

Ad hoc Reviewer: Steven A. Goldman, M.D., Ph.D., University of
 Rochester, Rochester, NY

Tab 2481 Protocol

Tab 2482 OBA Summary
 OBA Letter to PIs on In-Depth RAC Review and
 Public Discussion
 Reviews from Drs. Grant, Somia, Vile, and Goldman
 PIs' Response

9:35 AM **Public Comment**

Tuesday, December 4, 2007 (continued)

9:50 AM

Discussion of Human Gene Transfer Protocol #0710-880: A Phase I/IIA Study of the Safety and Efficacy of Neuroprogenitor Cells (SB623) in Patients with Stable Ischemic Stroke

PIs: Douglas Kondziolka, M.D., University of Pittsburgh, Pittsburgh, PA

Lawrence Wechsler, M.D., University of Pittsburgh, Pittsburgh, PA
(via teleconference)

RAC Reviewers: Eric Kodish, M.D.
Prediman Shah, M.D.
John Zaia, M.D.

Ad hoc Reviewer: Steven A. Goldman, M.D., Ph.D., University of Rochester, Rochester, NY

Tab 2483 Protocol

Tab 2484 OBA Summary
OBA Letter to PIs on In-Depth RAC Review and Public Discussion
Reviews from Drs. Kodish, Shah, Zaia, and Goldman
PIs' Response

11:20 AM

Public Comment

11:30 AM

Biosafety Working Group Update on Synthetic Biology

Presenter: Amy Patterson, M.D.
Director, Office of Biotechnology Activities

11:40 AM

LUNCH/RAC ORIENTATION

2:30 PM

Presentation on Use of Immunosuppression with AAV Vectors

Presenters: Katherine A. High, M.D., The Children's Hospital of Philadelphia, Philadelphia, PA

Sander van Deventer, M.D., Ph.D., University of Amsterdam, Amsterdam, The Netherlands

Tuesday, December 4, 2007 (continued)

3:15 PM

Discussion of Human Gene Transfer Protocol # 0707-864: *An Open-Label Dose-Escalation Study of a Self-Complementary Adeno-Associated Viral Vector (scAAV2/8-LPI-hFIXco) for Gene Therapy of Hemophilia B*

PI: Arthur W. Nienhuis, M.D., St. Jude Children's Research Hospital, Memphis, TN

RAC Reviewers: Stephen Dewhurst, Ph.D.
Hildegund Ertl, M.D.
Robyn Shapiro, J.D.
Scott Strome, M.D.

Ad hoc Reviewer: Barry J. Byrne, M.D., Ph.D., University of Florida, Gainesville, FL

Tab 2485 Protocol

Tab 2486 OBA Summary
OBA Letter to PI on In-Depth RAC Review and Public Discussion
Reviews from Drs. Dewhurst, Ertl, Strome, and Byrne and Ms. Shapiro
PI's Response

5:15 PM

Public Comment

5:30 PM

ADJOURNMENT

Wednesday, December 5, 2007

8:30 AM

Call to Order and Opening Remarks

Stephen Dewhurst, Ph.D., Acting Chair, NIH RAC

8:35 AM

Followup on the Consideration of a Proposed Major Action Under Section III-A-1 of the NIH Guidelines for Research Involving Recombinant DNA Molecules: Deliberate Transfer of Chloramphenicol Resistance to *Rickettsia conorii* and *Rickettsia typhi*

10:30 AM

Public Comment

10:45 AM

ADJOURNMENT